Published in final edited form as:

Alcohol Clin Exp Res. 2015 May ; 39(5): 808–817. doi:10.1111/acer.12703.

A Pilot Trial of Prazosin, an Alpha-1 Adrenergic Antagonist, for Comorbid Alcohol Dependence and Posttraumatic Stress Disorder

Tracy L. Simpson, PhD^{1,2,3,5}, Carol A. Malte, MSW¹, Bergetta Dietel, BA^{1,4}, Dana Tell, ARNP^{1,4}, Ian Pocock, BA^{1,4}, Robert Lyons, BA^{1,4}, Dana Varon, ARNP^{1,4}, Murray Raskind, MD^{2,3}, and Andrew J. Saxon, MD^{1,3}

¹Center of Excellence in Substance Abuse Treatment and Education, VA Puget Sound Health Care System

²Mental Illness Research Education and Clinical Center, VA Puget Sound Health Care System

³Department of Psychiatry and Behavioral Sciences, University of Washington

⁴Seattle Institute for Biomedical and Clinical Research

Abstract

Background—Posttraumatic Stress Disorder (PTSD) and alcohol dependence (AD) commonly co-occur and are associated with greater symptom severity and costs than either disorder alone. No pharmacologic interventions have been found to decrease both alcohol use and PTSD symptom severity relative to matched placebo. Prazosin, an alpha-1 adrenoreceptor antagonist, has demonstrated efficacy reducing PTSD and AD symptoms among individuals with one or the other disorder and may be useful in addressing comorbid PTSD/AD.

Methods—Prazosin and matched placebo were compared in the context of an outpatient 6-week double-blind randomized controlled pilot trial involving 30 individuals with comorbid PTSD/AD. Medication was titrated to 4mg q AM, 4mg q PM and 8mg qhs by the end of week 2. Participants in both conditions received five Medical Management sessions. Information regarding alcohol use, craving, and PTSD was gathered daily using a telephone Interactive Voice Response (IVR) system.

Results—Participants randomized to prazosin had a greater reduction in percent days drinking per week and percent days heavy drinking per week between baseline and week 6 than did placebo participants. No significant differences were detected within or between groups in change from weeks 1 to 6 in total PTSD symptoms. Participants in the prazosin condition reported drowsiness on significantly more days than those in the placebo condition.

Conclusions—Consistent with the extant research evaluating medications for comorbid PTSD/AD, the current evaluation of prazosin also found decreased alcohol consumption but no medication effect on PTSD symptomatology.

⁵Corresponding Author: Tracy L. Simpson, Ph.D., 1660 S. Columbian Way (116-ATC-S), Seattle, WA 98108; (206) 277-3337; Tracy.Simpson@va.gov.

Keywords

noradrenergic; prazosin; alcohol dependence; PTSD; human clinical trial

Posttraumatic stress disorder (PTSD) and alcohol dependence (AD) frequently co-occur. Estimates from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) indicate lifetime prevalence of PTSD/AD comorbidity in the U.S. of 1.59%, using DSM-IV criteria (Blanco et al., 2013). Compared with individuals with only one or the other disorder, those with both are more likely to have attempted suicide, to have additional psychiatric disorders, and to endorse more symptoms associated with both PTSD and AD (Blanco et al., 2013). Individuals with comorbid PTSD/AD also report greater disability and treatment seeking than those with AD only (Blanco et al., 2013; Drapkin et al., 2011).

Overview of Comorbid PTSD and Alcohol Use Disorders

Psychopharmacology

Despite the need for effective interventions to address PTSD/AD comorbidity, the current evidence base provides little guidance regarding optimum treatment for these patients (McCarthy and Petrakis, 2010; Norman et al., 2012; Sofuoglu et al., 2014). To date five published randomized clinical trials (RCT) have evaluated medications to treat comorbid PTSD/AUD (Batki et al., 2014; Brady et al., 2005; Foa et al., 2013; Petrakis et al., 2006; Petrakis et al., 2012). The results from these studies suggest that commonly used medications for AD (i.e., disulfiram, naltrexone, topiramate), as well as desipramine, confer some benefit on drinking outcomes for those with comorbid PTSD/AD. However, thus far, no medications appear to outperform placebo convincingly with regard to PTSD outcomes.

Noradrenergic Brain Systems are Implicated in Both AUD and PTSD

None of the aforementioned medications, except desipramine, directly target the noradrenergic system, which has integral involvement in the pathophysiology of both AUD and PTSD. Norepinephrine contributes substantially to the rewarding effects of alcohol (Ventura et al., 2006; Weinshenker et al., 2000). Proposed mechanisms posit that noradrenergic neurons in pre-frontal cortex project caudally to the ventral tegmental area and promote dopamine release into the nucleus accumbens (Ventura et al., 2003) and that norepinephrine, acting via α_1 -adrenergic receptors located pre-synaptically on dopaminergic neurons projecting to nucleus accumbens, directly drives dopamine release in that location (Mitrano et al., 2012). Norepinephrine levels in the periphery and in the central nervous system are elevated in animals and humans during alcohol withdrawal (Hawley et al., 1981; Kovacs et al., 2002; Patkar et al., 2003), and elevated norepinephrine levels in the extended amygdala are proposed to play a role in stress-induced relapse (Kash, 2012; Koob, 2009).

Among individuals with PTSD, the central nervous system is especially sensitive to noradrenergic activation in response to stress (Bailey et al., 2013; Strawn and Geraciotti, 2008), and elevated CNS noradrenergic activity is common at night and is associated with trauma-related nightmares (Cukor et al., 2009; Shad et al., 2011). Imaging research indicates that individuals with PTSD have decreased numbers of norepinephrine transporters on locus

coeruleus neurons (Pietrzak et al., 2013), which produce the majority of norepinephrine in the brain. Fewer transporters imply higher levels of norepinephrine available to bind to post-synaptic receptors.

Increased noradrenergic activity in AUD and PTSD provides a rationale for pharmacologic interventions that reduce noradrenergic activity. Prazosin, an α_1 adrenergic receptor antagonist, has been found to ameliorate PTSD-related nightmares and sleep disturbance and improves overall clinical status (Germain et al., 2012; Raskind et al., 2007; Raskind et al., 2013; Taylor et al., 2008). Prazosin also suppresses ethanol consumption by ethanol-dependent outbred male rats and by selectively bred ethanol-preferring male rats (Rasmussen et al., 2009). Prazosin additionally blocks reinstatement of alcohol consumption in response to stress among rats previously trained to self-administer alcohol (Le et al., 2011). Results from a pilot RCT of prazosin for alcohol dependence (without PTSD) indicate that prazosin is associated with significantly reduced alcohol consumption in men and is well tolerated (Simpson et al., 2009). A human laboratory trial involving recently abstinent, treatment seeking individuals with AD found that those receiving prazosin were less reactive to stress and reported lower alcohol craving when confronted with alcohol-related cues than those receiving placebo (Fox et al., 2012).

Petrakis conducted a double-blind RCT of prazosin for comorbid PTSD and AD among veterans (Petrakis, 2014) and found that, although both conditions were associated with decreased PTSD symptoms and decreased drinking over 12 weeks, there were no medication treatment effects. Because most participants were involved in either a partial hospitalization or a residential substance abuse program, the investigators concluded that treatment setting was a more powerful determinant of outcome than medication assignment. Thus, it is unclear whether prazosin would be beneficial to individuals with this comorbidity in outpatient settings where drinking is not constrained, and PTSD-related triggers are likely more abundant.

The current study was a pilot double-blind RCT comparing prazosin to placebo using outpatient Medical Management (MM; Anton et al., 2006) as the behavioral platform and a daily Interactive Voice Response (IVR) telephone monitoring system for daily assessment over the course of treatment. We hypothesized that participants in the prazosin condition would show greater improvement over the study course in alcohol use, craving, and PTSD symptoms relative to those randomized to placebo.

Materials and Methods

Participants

A total of 354 people inquired about the study, 54 provided written consent and completed an in-person screen, and 30 were eligible and randomized (Figure 1). The 19 men and 11 women were between the ages of 21–59 ($M \pm SD$ age = 43.3 ± 11.7) and met inclusion criteria including current DSM-IV diagnoses of AD and PTSD (APA, 2000) and recent alcohol consumption at or above 14 (women) or 21 (men) drinks per week AND at least 2 days of heavy drinking (>4 drinks per occasion for women and >5 drinks for men) over a 30 day period in the last 90 days.

Study exclusion criteria were as follows: 1) uncontrolled psychosis or mania; 2) current opioid dependence or abuse or positive urine screen (UDAS) for opioids, methamphetamines, benzodiazepines or sedative hypnotics; 3) systolic blood pressure <110mmHg or pre-existing orthostatic hypotension; 4) health conditions including unstable angina, Meniere's disease, narcolepsy, benign positional vertigo, chronic renal or hepatic failure, pancreatitis or insulin-dependent diabetes mellitus, 5) use of any anti-alcohol medication (e.g., naltrexone, acamprosate, or disulfiram), 6) unstable psychiatric medication regimen in the past month, 9) engagement in trauma-focused PTSD treatment or behaviorally focused addiction treatment, and 10) for males only, concomitant use of trazodone, tadalafil, or vardenafil due to increased risk of priapism. Female participants of child-bearing age were excluded unless they reported using a birth control method judged by the study clinician to be effective. During their 6 weeks of medication, all subjects were asked to forgo any concurrent behavioral or pharmacological treatment for AD or PTSD other than Alcoholics Anonymous (AA) and concurrent supportive therapy or counseling.

Procedures

The study was originally designed as a 12-week trial (2 weeks dose titration, 10 weeks achieved dose). However, participants had greater difficulty than expected adhering to this protocol length, with 39% withdrawing prior to week 12. After enrolling 18 participants we scaled back to 6 weeks of active medication (2 weeks dose titration, 4 weeks achieved dose). The decision to reduce the study to 6 weeks was made without breaking the study blind; thus we did not know at the time whether there was differential drop-out based on group assignment. We present the procedures and results through week 6 here for all 30 participants. With regard to study completion for the 12-week timeframe, 45.5% of those in the prazosin condition completed and 85.7% of those in the placebo condition completed. For participants who entered the study after the transition to the 6-week timeframe, 100% of those in the prazosin condition completed and 62.5% of those in the placebo condition completed.

Recruitment and screening—Human subjects approval was provided by the institutional review board at the VA Puget Sound Health Care System. Participants were recruited between June 2010 and June 2012 through advertisements in local newspapers and posted flyers. The study is registered through [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT01518972) (NCT01518972).

After signing the informed consent and demonstrating a breath alcohol level of 0, participants underwent screening, which consisted of a physical examination; a medical history; diagnostic measures of substance dependence and abuse and psychiatric disorders, and laboratory assessment of CBC, liver function panel, and urine pregnancy. A UDAS test cup was used to screen for controlled substances.

Those found eligible at screening were invited to participate in a baseline assessment to complete additional study measures and receive study medication.

Randomization—Participants were randomized to prazosin or placebo by our center's research pharmacist. Randomization was stratified by gender, veteran status, and >10 days

of drinking in the last 30 days. All study personnel and participants remained blind to participants' group assignment throughout the course of the study.

Study Visits—During weeks 1–2, participants completed twice weekly study visits that decreased to weekly for weeks 3–6 for a total of 10 visits for the 6-week study length. All visits included orthostatic vital sign checks and adverse events monitoring. To ascertain likely medication compliance pill counts were conducted, and participant urine toxicology specimens were examined for presence of a riboflavin tracer added to all study medication. Participants were classified as receiving a full course of medication treatment if they received study medication at the week 4 visit to last through week 6.

Measures

Mental health diagnoses and symptoms—The “Substance Use Disorder” and “Psychotic and Associated Symptoms” sections of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-1; First et al., 1995) were administered at screening to assess diagnosis of alcohol dependence, opioid abuse or dependence, schizophrenia, schizoaffective, or schizophreniform disorder. To assess current PTSD diagnostic status, we administered the Life Events Checklist (Blake et al., 1995) to ascertain trauma exposure and the PTSD Symptom Scale-Interview Version (PSS-I; Foa et al., 1993); the PSS-I includes 17 items that assess the frequency and severity of PTSD symptoms. Item responses range from 0 (not at all) to 3 (5 or more times per week/very much) and total scores range from 0 to 51.

Substance use and craving—The Form-42 was adapted from the Form-90 (Miller and Del Boca, 1994) and uses the timeline follow-back and steady drinking pattern methods to assess alcohol use and treatment for 6 weeks prior to baseline and at follow-up for the 6 weeks of study involvement. The Penn Alcohol Craving Scale (PACS; Flannery et al., 1999) was used to assess craving at baseline.

IVR Daily Monitoring—Daily IVR symptom monitoring was used to track outcomes. Participants were given a watch with preset alarms to remind them to take their medication and call a toll-free number to report on their alcohol craving (4 items from the PACS adapted to the daily timeframe), daily alcohol use (beer, wine, spirits queried separately and totaled), PTSD (12 symptoms adapted from the PTSD Checklist-Civilian version (Weathers et al., 1993), the degree to which alcohol was reinforcing on drinking days (4 items; Ray and Hutchison, 2007), reasons for not drinking on non-drinking days (6 yes/no items), and medication compliance (1 item ranging from 0 to 3 doses) over the prior 24 hours. Items assessing craving, PTSD symptoms and alcohol reinforcement followed a Likert scale, with minimum response of 0 indicating “not at all” and a maximum response of 8 indicating “extremely.”

Study Treatments

Medications—Medications were titrated to a target dose of 4mg q AM, 4mg q PM and 8mg qhs (or highest tolerated dose) by the end of week 2, which was continued for an additional 4 weeks. Dosing was held at 1mg qhs for the first two nights to minimize the chance of first-dose syncope. Participants' titration was slowed if they experienced

symptomatic orthostatic hypotension or intolerable side effects; the prior titration could resume at cessation of participants' reported side effects. Dosing was targeted for three times per day because prazosin has a short half-life (Jaillon, 1980), and steady noradrenergic antagonism during likely drinking times was indicated to test the medication effects on the target behavior.

Placebo and study medication were identically matched and were prepared by a local compounding pharmacy. Quality assurance testing was done by the VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center in Albuquerque, NM. Prazosin concentration in 2 and 4 mg capsules measured by high performance liquid chromatography (HPLC) had a coefficient of variation of <6%.

Medical Management—Participants received 5 MM counseling visits with a study clinician over the course of the 6-week study.

Outcomes

Primary outcomes were change in self-reported percent drinking days per week and percent heavy drinking days per week between baseline and week 6. Heavy drinking was defined as 5 or more drinks per day for men and 4 or more drinks per day for women. We also evaluated the number of standard drinks per week over the 6-week study period. Drinking data were collected via the Form 42 at baseline and via IVR daily monitoring at weeks 1 through 6. Weekly IVR data were treated as missing if participants called in on fewer than four days in a given week. However, in these cases we used data from the follow-up Form-42 so that some drinking information about those otherwise missing weeks could be included in the models. Secondary outcomes were changes in PTSD symptomology, including total symptoms, re-experiencing, avoidance/numbing, hypervigilance and a single dream item, and changes in average craving per week via IVR daily monitoring. PTSD scores were derived by computing the daily average of the item totals for overall PTSD and the symptom clusters so that each score is scaled to the original 0 to 8 metric. Exploratory analyses evaluated average rating of alcohol reinforcement on drinking days (i.e., degree of satisfaction, enjoyment, liking, and high associated with alcohol consumption), and percent endorsement of reasons associated with not drinking on non-drinking days (i.e., (1) alcohol was not appealing or no had desire to drink; (2) having no money or opportunity to drink or being ill, and (3) wish to maintain sobriety).

Data Analysis

All primary analyses were examined for the entire sample as randomized (intent-to-treat) and for participants receiving the full course of medication through week 6 (n=20).

Demographic, baseline, and compliance variables are presented descriptively. Differences between the placebo and prazosin groups were analyzed with the Chi-square statistic for categorical variables and with Student's t-test for continuous variables.

Longitudinal drinking (percent any and heavy drinking days per week) and craving outcomes between baseline and week 6 were examined using multilevel mixed-effects linear regression models with random slope that included treatment group, time, and treatment

group X time interaction. Time was modeled as a categorical variable. We used similar multilevel mixed-effects linear regression models to examine change by condition in PTSD outcomes (total score, re-experiencing, avoidance/number, hypervigilance and the dream item) between weeks 1 and 6; because measures comparable to the IVR PTSD measures were not available at baseline, models were adjusted for baseline PTSD severity as measured by corresponding PSS-I scores and sub-scores (i.e. analyses of change in re-experiencing were adjusted by the baseline PSS-I re-experiencing score). Because women and men have been found to respond differently to medications for AD (Garbutt et al., 2005), analyses were adjusted for gender.

Exploratory analyses examining average alcohol reinforcement on drinking days and percent endorsement of reasons associated with not drinking on non-drinking days between weeks 1 and 6 were each examined using linear regression models adjusted for baseline craving levels as measured by the PACS.

Blood pressure was evaluated across groups at baseline by Student's t-test as were average changes in blood pressure from week 1 to week 6. Percent of patients experiencing core adverse events (dizziness on standing, headache, lightheadedness, nausea, lack of energy, drowsiness, blood pressure drop sitting to standing) between weeks 1 and 6 were compared across conditions using Chi-square statistics. In addition, the mean number of days that participants in each condition experienced each adverse event was compared using Student's t-tests.

Analyses were conducted with Stata version 13.1 (StataCorp LP, College Station, TX) and SPSS 22 for Windows (SPSS Inc., Chicago, IL). Two-sided p-values of < 0.05 were considered statistically significant and statistical trends at the $p < .10$ level are noted.

Results

Baseline Group Comparisons

The prazosin and placebo groups did not differ significantly with respect to demographic characteristics, the amount or frequency of drinking, or PTSD severity at baseline (Table 1). The two groups did not differ with regard to number of traumas that met the Criterion A requirements for a PTSD diagnosis (Table 2). Those in the prazosin condition endorsed higher craving levels at baseline. Additionally, at baseline 10 participants in the prazosin condition and 9 in the placebo condition reported receiving some supportive therapy in the past 90 days. With regard to concurrent medications reported at baseline, 2 participants in each condition reported use of the noradrenergic blood pressure medication atenolol, 5 prazosin and 2 placebo participants were on an antidepressant, and 2 prazosin participants were prescribed stimulants (one for chronic fatigue and the other for weight loss). Overall, 5 prazosin and 2 placebo participants were on at least one psychiatric medication at baseline.

Completion and Compliance Rates

Twenty of the 30 (66.7%) randomized individuals received study medication through week 6, with somewhat higher rates of completion in the placebo condition [prazosin: 9 (60.0%); placebo: 11 (73.3%), ns]. The compliance rate on the IVR daily monitoring was 77.0%

(prazosin: 70.6%, placebo: 83.5%, *ns*) between randomization and week 6 (or date of termination for those who dropped prior to week 6). Among participants who received medication at the week 4 visit, the IVR compliance rate was 90.5% (prazosin: 86.2%, placebo: 93.9%, *ns*). The two groups did not differ significantly on medication compliance via riboflavin trace, pill counts, or daily IVR monitoring, nor on safety visits attended.

Drinking Outcomes

As seen in Figure 2 and Table 3, participants randomized to prazosin had a greater reduction in percent drinking days per week between baseline and week 6 than did those randomized to placebo [$\chi^2(6)=19.3$, $p=0.004$]. The difference remained significant when only those receiving medication at the week 4 visit were included [$n=20$, $\chi^2(6)=26.4$, $p<0.001$]. Participants randomized to prazosin also showed a greater reduction in percent heavy drinking days per week relative to those randomized to placebo [$\chi^2(6)=21.3$, $p=0.002$], which held among those receiving medication at the week 4 visit [$\chi^2(6)=28.4$, $p<0.001$]. Estimated average drinks per week fell from 80.3 to 7.9 in the prazosin condition, compared to a drop from 50.0 to 27.0 in the placebo condition [$\chi^2(6)=19.0$, $p=0.004$].

This same pattern of results was seen for the 7–12 week timeframe for the 10 participants (5 in each condition) enrolled in the 12-week trial with adequate data, whereby those in the prazosin condition reported significantly less drinking over time than those assigned to placebo. Specifically, the prazosin participants reported lower percent drinking days ($M=13.0$, $SD=14.7$) compared to the placebo participants ($M=46.1$, $SD=25.4$) between weeks 7 and 12. Likewise, the percent of heavy drinking days was lower in the prazosin condition ($M=2.1$, $SD=4.6$) compared to the placebo condition ($M=18.3$, $SD=22.3$).

PTSD Symptom Change

As shown in Table 3, after adjusting for baseline scores and gender, no differences were detected within or between groups in change from weeks 1 to 6 in total PTSD symptoms or the PTSD symptom clusters (hypervigilance, avoidance/numbing, re-experiencing or the dream item). The same pattern of results was seen among those who received medication at the week 4 visit.

Potential Treatment Mediators and Craving, Alcohol Reinforcement, and Reasons Associated with Not Drinking

Both groups experienced a drop in craving between baseline and week 6 [$\chi^2(6)=47.2$, $p<0.001$]; while the prazosin condition tended to experience a greater decrease in craving relative to the placebo condition, the difference between conditions in change over time was only at the trend level [$\chi^2(6)=11.9$, $p=0.064$]. We did not find significant differences between the prazosin and placebo conditions on the average degree of reinforcement associated with alcohol consumption on drinking days between weeks 1 and 6 (see Table 4). With regard to reasons for not drinking, after adjusting for baseline craving, the average percent of non-drinking days that “alcohol was not appealing or no desire to drink” was endorsed as a reason for not drinking between weeks 1 and 6 was higher in the prazosin condition than the placebo condition. No differences were seen between conditions in

endorsement of lack of money/lack of opportunity/illness or maintaining sobriety as reasons for not drinking.

Safety Findings

There were two non-study related serious adverse events: one psychiatry admission for suicidality and one admission for surgery for a pre-existing condition. The most frequently reported side effects were headaches, nausea, lightheadedness, and drowsiness (see Table 5). The prazosin group endorsed significantly higher mean number of days of drowsiness relative to placebo as well as higher mean days of dizziness on standing and low energy, both the latter two at the trend level ($p < 0.10$). Those in the prazosin condition reported the presence of three or more adverse events at nearly 25% (SD 33.1) of the study visits vs. 13% (SD 10.6) for the placebo condition (*ns*). Six participants (4 women, 2 men) in the prazosin condition and one man in the placebo condition received downward dose adjustments. One placebo participant stopped study medication at day 12 but completed all study visits.

There were no differences in blood pressure (BP) at baseline between the two conditions, and there were also no between group differences in BP changes from baseline to the six-week safety check across the two conditions. There was one instance observed by a study clinician of orthostatic hypotension including a systolic drop of greater than 20mmHg for a male prazosin participant addressed effectively by dose reduction (4mg, 4 mg, 4 mgs).

Discussion

This pilot study evaluated whether the α -1 adrenergic antagonist, prazosin, was useful in reducing drinking behavior and PTSD symptomatology among individuals with comorbid AD and PTSD. Although participants in both conditions improved over time on drinking outcomes, the results indicate that prazosin conferred significant benefit over and above placebo with regard to the percent drinking days per week, percent heavy drinking days per week, and the number of drinks consumed per week. This pattern was found in the main intent-to-treat analyses as well as in the analyses involving only those who received medication through the week 4 visit. The results, however, do not indicate that prazosin was helpful in reducing PTSD symptomatology.

We also found that 60% those in the prazosin condition completed the six-week treatment window and 73% of those in the placebo condition did so. Six individuals in the prazosin condition required dose reductions, and those in the prazosin condition reported significantly greater number of days of drowsiness than those assigned to placebo. We also saw a similar pattern with regard to lack of energy and dizziness at the trend level. These findings are not consistent with a previous study evaluating prazosin among individuals with AD only (see Simpson et al., 2009). Thus, despite promising findings with regard to drinking outcomes, prazosin at the target dosage of 4mg q AM, 4 mg q PM, and 8 mg qhs may be difficult for some PTSD/AD patients to tolerate during the day, and it does not appear to be optimal for addressing PTSD symptoms.

The present findings are, however, generally consistent with the extant literature pertaining to medications for the treatment of comorbid PTSD/AD. Most of the previous research has

found some improvement on drinking outcomes for the active medications vs. placebo but no strong evidence of additional benefit of these medications over placebo for PTSD outcomes (Brady et al., 2005; Foa et al., 2013; Petrakis et al., 2006; Petrakis et al., 2012), though Batki et al. (2014) found a trend regarding PTSD hyperarousal symptoms favoring topiramate. While it is noteworthy that individuals with comorbid PTSD/AD can realize some improvement with regard to their drinking from a variety of medications, PTSD symptomatology is not as readily attenuated. For those individuals whose drinking is motivated at least in part by self-medication of their PTSD symptomatology (see Simpson et al., 2014), persistently elevated PTSD symptoms likely increases risk for relapse and thus represent a high priority target for improved interventions.

Given previous research that prazosin is helpful for ameliorating PTSD symptomatology (Germain et al., 2012; Raskind et al., 2013; Taylor et al., 2008), the present negative results were unexpected. It is possible that the dosing schedule used in the present study that included a maximum of 8mg at bedtime was not sufficient to fully impact the hallmark nightmares and sleep disturbance associated with PTSD. Raskind and colleagues (2013) titrated to a maximum nighttime dose of 20mg of prazosin for men and 10mg for women (no daytime doses were included). Dose ranging studies are needed to ascertain the optimal dosing regimen for prazosin for PTSD/AUD. In light of the prior work on PTSD and the findings from the current study, we posit that lowering the doses during the day to reduce drowsiness, in particular, along with increasing the final nighttime dose to better address nightmares and other sleep disturbance associated with PTSD would be reasonable to evaluate in further research.

Another possible explanation for the lack of congruence on PTSD outcomes across prazosin studies is that most of the previous work on this medication for PTSD has included veteran or civilian samples with more clearly delineated focal traumas than was the case in the present study. Well over half the individuals in our sample reported 3 or more traumatic experiences that met DSM-IV Criterion A requirements, and most reported at least one trauma experience prior to age 18, signaling that this group has complex trauma histories, many of which were of a very personal nature (sexual assault, physical assault) that may not be amenable to the same interventions as those with more discrete trauma histories. It is also conceivable that, since all participants in this study were trying to reduce alcohol use, subclinical alcohol withdrawal symptoms occurred that were misinterpreted by participants as PTSD symptoms given the known overlap between the two (Jacobsen et al., 2001).

Most of the other medication trials involving individuals with comorbid PTSD/AD found overall improvements in PTSD outcomes (Batki et al., 2014; Foa et al., 2013; Petrakis et al., 2006; Petrakis et al., 2012), although as noted above, the active medications for the most part did not outperform placebo. In the present study, we did not find a main effect of time with regard to PTSD. It is possible that the lack of a robust behavioral treatment platform directed at PTSD was partly responsible for this finding.

With regard to secondary outcomes, although we did not find a strong indication that prazosin conferred an advantage over placebo for alcohol craving, there was a trend on this outcome favoring prazosin. We also found that on non-drinking days, those in the prazosin

condition were significantly more likely to report that the idea of alcohol was not appealing than were those in the placebo condition. Not drinking due to other issues did not differ by condition. We did not find differences between the two conditions with regard to the reinforcing qualities of alcohol on drinking days despite pre-clinical studies indicating that norepinephrine plays a role in alcohol's reinforcing effects (Ventura et al., 2006; Weinshenker et al., 2000). These findings together suggest that rather than causing alcohol to be less satisfying or enjoyable when it is consumed, at least in humans with PTSD, prazosin may be dampening interest in drinking on non-drinking days and lowering craving.

The present study has some strengths along with some limitations that need to be considered. With regard to strengths, we included a varied and quite severe actively drinking study sample that closely resembles individuals with PTSD/AD comorbidity who are likely to be seeking clinical care. Additionally, these individuals were treated in an outpatient setting and did not have to be abstinent to initiate study engagement, both of which are typical for individuals presenting for clinical care. We also included a daily monitoring symptom assessment protocol that allowed us to capture information on drinking and PTSD symptoms in close to real time. The limitations include the small sample size and somewhat poor study retention. Further, we found that compliance with the daily monitoring was poorer than found in previous clinical trials with either AD only (Simpson et al., 2009) or PTSD/AD comorbidity (Stappenbeck et al., 2014), which raises concerns regarding the influence of missing data on the findings. These concerns are mitigated by the fact that our drinking analyses of those who received medication at the week 4 visit where IVR compliance was very strong were virtually identical to the intent-to-treat analyses.

In conclusion, the present study found that prazosin produced better drinking outcomes among individuals with comorbid PTSD/AD than did placebo. However, this positive finding is tempered by the lack of effect on PTSD symptoms. Since prazosin has shown efficacy for PTSD alone in other studies, additional research using it or other α_1 adrenergic antagonist for treatment of comorbid PTSD/AD in larger sample sizes exploring different dosing regimens appears warranted.

Acknowledgments

Funding for this study was provided by a grant awarded to Dr. Saxon (NIAAA P20 1 P20 AA017839-01) and the VA Puget Sound Health Care System, Seattle, Washington Center of Excellence in Substance Abuse Treatment and Education.

References

- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed text rev. Washington, DC: 2000.
- Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A. COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the combine study: a randomized controlled trial. JAMA. 2006; 295(17):2003–2017. [PubMed: 16670409]
- Bailey CR, Cordell E, Sobin SM, Neumeister A. Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment. CNS Drug. 2013; 27(3):221–232.

- Batki SL, Pennington DL, Lasher B, Neylan TC, Metzler T, Waldrop A, Delucchi K, Herbst E. Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial. *Alcohol Clin Exp Res*. 2014; 38(8):2169–2177. [PubMed: 25092377]
- Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM. The development of a clinician-administered PTSD scale. *Jour of Traum Str*. 1995; 8:75–90.
- Blanco C, Xu Y, Brady K, Pérez-Fuentes G, Okuda M, Wang S. Comorbidity of posttraumatic stress disorder with alcohol dependence among US adults: results from national epidemiological survey on alcohol and related conditions. *Drug Alcohol Depend*. 2013; 132(3):630–638. [PubMed: 23702490]
- Brady KT, Sonne S, Anton RF, Randall CL, Back SE, Simpson K. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. *Alcohol Clin Exp Res*. 2005; 29(3):395–401. [PubMed: 15770115]
- Cukor J, Spitalnick J, Difede J, Rizzo A, Rothbaum BO. Emerging treatments for PTSD. *Clin Psychol Rev*. 2009; 29(8):715–726. [PubMed: 19800725]
- Drapkin ML, Yusko D, Yasinski C, Oslin D, Hembree EA, Foa EB. Baseline functioning among individuals with posttraumatic stress disorder and alcohol dependence. *Jour Subst Abuse Treat*. 2011; 41(2):186–192. [PubMed: 21546205]
- First, MB.; Spitzer, RL.; Gibbon, M.; Williams, JBW. Structured Clinical Interview for Axis I DSM-IV Disorders, Patient Edition (SCID-I/P). Biometrics Research Department, NY State Psychiatric Institute; 1995.
- Flannery BA, Volpicelli JR, Pettianati HM. Psychometric properties of the Penn Alcohol Craving Scale. *Alcohol Clin Exp Res*. 1999; 23(8):1289–1295. [PubMed: 10470970]
- Foa EB, Riggs DS, Dancu CV, Rothbaum BO. Reliability and validity of a brief instrument for assessing post-traumatic stress disorder. *Jour of Traum Stress*. 1993; 6(4):459–473.
- Foa EB, Yusko DA, McLean CP, Suvak MK, Bux DA Jr, Oslin D, O'Brien CP, Imms P, Riggs DS, Volpicelli J. Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial. *JAMA*. 2013; 310(5):488–95. [PubMed: 23925619]
- Fox HC, Anderson GM, Tuit K, Hansen J, Kimmerling A, Siedlarz KM, Morgan PT, Sinha R. Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. *Alcohol Clin Exp Res*. 2012; 36(2):351–360. [PubMed: 21919922]
- Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW. Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. *JAMA*. 2005; 293(13):1617–1625. [PubMed: 15811981]
- Germain A, Richardson R, Moul DE, Mammen O, Haas G, Forman SD, Rode N, Begley A, Nofzinger EA. Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US military veterans. *J Psychosom Res*. 2012; 72(2):89–96. [PubMed: 22281448]
- Hawley RJ, Major LF, Schulman EA, Lake CR. CSF levels of norepinephrine during alcohol withdrawal. *Arch Neurol*. 1981; 38(5):289–292. [PubMed: 7224914]
- IBM SPSS Statistics for Windows. Version 22.0. Armonk, NY: IBM Corporation; 2013.
- Jacobsen LK, Southwick SM, Kosten TR. Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. *Am Jour Psychiat*. 2001; 158(8):1184–1190. [PubMed: 11481147]
- Jaillon P. Clinical pharmacokinetics of prazosin. *Clin Pharmacoki*. 1980; 5(4):365–376.
- Kash TL. The role of biogenic amine signaling in the bed nucleus of the stria terminals in alcohol abuse. *Alcohol*. 2012; 46(4):303–308. [PubMed: 22449787]
- Koob GF. Brain stress systems in the amygdala and addiction. *Brain Res*. 2009; 1293:61–75. [PubMed: 19332030]
- Kovacs GL, Soroncz M, Tegyei I. Plasma catecholamines in ethanol tolerance and withdrawal in mice. *Eur Jour Pharmacol*. 2002; 448(2–3):151–156. [PubMed: 12144935]

- Lê AD, Funk D, Juzytsch W, Coen K, Navarre BM, Cifani C, Shaham Y. Effect of prazosin and guanfacine on stress-induced reinstatement of alcohol and food seeking in rats. *Psychopharm (Berl)*. 2011; 218(1):89–99.
- McCarthy E, Petrakis I. Epidemiology and management of alcohol dependence in individuals with post-traumatic stress disorder. *CNS Drugs*. 2010; 24(12):997–1007. [PubMed: 21090836]
- Miller WR, Del Boca FK. Measurement of drinking behavior using the Form 90 family of instruments. *Jour Stud Alcohol Suppl*. 1994; 12:112–118. [PubMed: 7722987]
- Mitrano DA, Schroeder JP, Smith Y, Cortright JJ, Bubula N, Vezina P, Weinshenker D. Alpha-1 adrenergic receptors are localized on presynaptic elements in the nucleus accumbens and regulate mesolimbic dopamine transmission. *Neuropsychopharm*. 2012; 37(9):2161–2172.
- Norman SB, Myers US, Wilkins KC, Goldsmith AA, Hristova V, Huang Z, McCullough KC, Robinson SK. Review of biological mechanisms and pharmacological treatments of comorbid PTSD and substance use disorder. *Neuropharm*. 2012; 62:542–551.
- Patkar AA, Gopalakrishnan R, Naik PC, Murray HW, Vergare MJ, Marsden CA. Changes in plasma noradrenaline and serotonin levels and craving during alcohol withdrawal. *Alcohol and Alcoholis*. 2003; 38(3):224–231.
- Petrakis, IL. Pharmacotherapy for PTSD and substance abuse among veterans. In the New Clinical Drug Evaluation Unit; 54th Annual meeting of the New Clinical Drug Evaluation Unit Conference; Hollywood, FL. 2014.
- Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Ralevski E, Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. *Biol Psychiat*. 2006; 60(7):777–783. [PubMed: 17008146]
- Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B, Krystal JH. Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. *Neuropsychopharm*. 2012; 37(4):996–1004.
- Pietrzak RH, Gallezot JD, Ding YS, Henry S, Potenza MN, Southwick SM, Krystal JH, Carson RE, Neumeister A. Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. *JAMA Psychiat*. 2013; 70(11):1199–1205.
- Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, Shofer J, O'Connell J, Taylor F, Gross C, Rohde K, McFall ME. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. *Biol Psychiat*. 2007; 61(8):928–934. [PubMed: 17069768]
- Raskind MA, Peterson K, Williams T, Hoff DJ, Hart K, Holmes H, Thomas D, Hill J, Daniels C, Calohan J, Millard SP, Rohde K, O'Connell J, Pritzl D, Feiszli K, Petrie EC, Gross C, Mayer CL, Freed MC, Engel C, Peskind ER. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. *Am J Psychiat*. 2013; 170(9):1003–1010. [PubMed: 23846759]
- Rasmussen DD, Alexander LL, Raskind MA, Froehlich JC. The alpha-1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats. *Alcohol Clin Exp Res*. 2009; 33(2):264–272. [PubMed: 19032582]
- Ray L, Hutchison K. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response. *Arc of Gen Psych*. 2007; 64(9):1069–1077.
- Shad MU, Suris AM, North CS. Novel combination strategy to optimize treatment for PTSD. *Hum Psychopharm*. 2011; 26(1):4–11.
- Simpson TL, Saxon AJ, Meredith CW, Malte CA, McBride B, Ferguson LC, Gross CA, Hart KL, Raskind M. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. *Alcohol Clin Exp Res*. 2009; 33(2):255–263. [PubMed: 18945226]
- Simpson TL, Stappenbeck CA, Luterek JA, Lehavot K, Kaysen DL. Drinking motives moderate daily relationships between PTSD symptoms and alcohol use. *Jour Abnorm Psychol*. 2014; 123(1):237–247. [PubMed: 24661174]
- Sofuoglu M, Rosenheck R, Petrakis I. Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress. *Addict Behav*. 2014; 39(2):428–433. [PubMed: 24035645]
- Stata Statistical Software. Release 13. College Station, TX: Stata Corp LP; 2013.

- Stappenbeck, CA.; Luterek, JA.; Kaysen, D.; Rosenthal, CF.; Gurrad, B.; Simpson, TL. Behav Res Ther. A controlled examination of two coping skills for daily alcohol use and PTSD symptom severity among dually diagnosed individuals. (in press)
- Strawn JR, Geraciotti TD Jr. Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder. *Depress Anxiety*. 2008; 25(3):260–271. [PubMed: 17354267]
- Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C, Peskind ER, Raskind MA. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. *Biol Psychiat*. 2007; 63(6):629–632. [PubMed: 17868655]
- Ventura R, Cabib S, Alcaro A, Orsini C, Puglisi-Allegra S. Norepinephrine in the prefrontal cortex is critical for amphetamine-induced reward and mesoaccumbens dopamine release. *J Neurosci*. 2003; 23(5):1879–1885. [PubMed: 12629192]
- Ventura R, De Carolis D, Alcaro A, Puglisi-Allegra S. Ethanol consumption and reward depend on norepinephrine in the prefrontal cortex. *Neurorep*. 2006; 17(17):1813–1817.
- Weathers, FW.; Litz, BT.; Herman, DS.; Huska, JA.; Keane, TM. The PTSD Checklist (PCL): reliability, validity, and diagnostic utility. International Society of Traumatic Stress; 9th annual meeting of the International Society for Traumatic Stress Studies; San Antonio, TX. 1993.
- Weinshenker D, Rust NC, Miller NS, Palmiter RD. Ethanol-associated behaviors of mice lacking norepinephrine. *J Neurosci*. 2000; 20(9):3157–3164. [PubMed: 10777779]

Figure 1.
Study Consort Diagram

Figure 2.

Patients randomized to prazosin had a greater reduction in percent drinking days per week [$\chi^2(6)=19.3$, $p=0.004$] and percent heavy drinking days per week [$\chi^2(6)=21.3$, $p=0.002$] between baseline and 6 weeks than those randomized to placebo after adjusting for gender.

Table 1

Demographics and Baseline Characteristics

Characteristics	Placebo (n=15)	Prazosin (n=15)	p-value
	M(SD) or n(%)	M(SD) or n(%)	
Age	43.5(12.4)	43.1(11.3)	ns
Race			ns
White	4(26.7)	8(53.3)	
Black	8(53.3)	4(26.7)	
Other	3(20.0)	3(20.0)	
Female	5(33.3)	6(40.0)	ns
Veteran	5(33.3)	4(26.7)	ns
Marital Status			ns
Never Married	8(53.3)	6(42.9)	
Married	0(0.0)	2(14.3)	
Divorced/Separated	5(33.3)	6(42.9)	
Other	2(13.3)	0(0.0)	
Employment			ns
Employed	0(0.0)	2(14.3)	
Disability/Pension	7(50.0)	7(50.0)	
Unemployed	7(50.0)	3(21.4)	
Other	0(0.0)	2(14.3)	
College/Post Graduate Education	12(80.0)	11(78.6)	ns
Living Situation			ns
Stably housed	12(85.7)	10(66.7)	
Homeless	1(7.1)	2(13.3)	
Other	1(7.1)	3(20.0)	
Drinks per day, past 90 days	8.5(5.1)	11.0(10.8)	ns
Total drinks, past 7 days	49.6(44.6)	80.1(75.1)	ns
Drinking days, past 7 days	4.2(2.8)	5.1(1.7)	ns
PACS (craving) score	17.5(6.8)	22.1(4.5)	0.037
PSS-I (PTSD) score	31.6(7.7)	31.5(8.9)	ns

Table 2

Trauma exposures by condition and total sample.

Trauma Type	Placebo	Prazosin	Total
Physical Assault	100.0%	93.3%	96.7%
Weapon Assault	80.0%	60.0%	70.0%
Natural Disaster	40.0%	73.3%	56.7%
Transportation Accident	66.7%	66.7%	66.7%
Sexual Assault	66.7%	60.0%	63.3%
Witnessing Sudden Violent Death	33.3%	66.7%	50.0%
Serious Work Accident	33.3%	53.3%	43.3%
Fire or Explosion	26.7%	26.7%	26.7%
Combat Exposure	20.0%	20.0%	20.0%
<i>3 or more Criterion A</i>	53.3%	60.0%	63.3%
<i>1 or more childhood trauma</i>	86.7%	73.3%	80.0%

Table 3Estimated^a mean baseline and week 6 drinking and PTSD scores.

	Placebo		Prazosin	
	Est. Mean (95% CI)		Est. Mean (95% CI)	
	Baseline^a	Week 6	Baseline^a	Week 6
<i>Drinking Outcomes</i>				
Percent Drinking Days per Week	59.7(43.0–76.4)	49.3(31.7–66.9)	73.4(56.7–90.1)	18.1(–1.1–37.4) *
Percent Heavy Drinking Days per Week	50.6(35.7–65.6)	27.4(11.3–43.5)	67.6(52.7–82.5)	3.7(–14.4–21.8) *
Drinks per Week	50.0(30.3–69.7)	27.0(5.9–48.1)	80.3(60.7–100.0)	7.9(–15.7–31.4) *
<i>PTSD Outcomes^b</i>				
Total PTSD Score	2.7(1.6–3.8)	2.5(1.4–3.6)	3.7(2.6–4.8)	3.1(1.9–4.2)
Re-experiencing	2.6(1.4–3.8)	2.6(1.4–3.8)	3.8(2.7–5.0)	3.2(1.9–4.4)
Avoidance/Numbing	2.7(1.5–3.9)	2.4(1.2–3.6)	3.6(2.4–4.8)	2.9(1.6–4.2)
Hypervigilance	2.8(1.7–3.9)	2.4(1.3–3.6)	3.6(2.5–4.8)	3.2(2.0–4.4)
Disturbing Dreams	2.4(1.1–3.7)	2.8(1.5–4.1)	3.2(1.9–4.6)	2.5(1.0–3.9)

^aThe PTSD outcomes include those with adequate IVR data at Week 1 (at least 4 of 7 days completed; n = 26)^bWeek 1 IVR scores are presented for PTSD rather than baseline PSS-I scores because the daily IVR questions and the PSS-I interview items were scaled differently

* p<0.01

Table 4

Potential Treatment Mediators

	Placebo	Prazosin
Potential Treatment Mediators	Mean (95% CI)	Mean (95% CI)
Change in IVR PACS score baseline to week 6	-1.1(-2.0,-0.3)	-2.4(-3.4,-1.4)
Average alcohol reinforcement (n=24) on drinking days	3.9(3.2,-4.6)	4.5(3.4,-5.5)
Reasons for Not Drinking (n=28)	% of non-drinking days endorsed	
no desire/not appealing	35.9(16.1,55.8)	67.7(48.6,86.8) *
lack of money, opportunity, illness	54.7(37.1,72.4)	37.4(15.7,59.1)
maintain sobriety	51.7(27.6,75.9)	66.8(44.1,89.5)

*
p = 0.029

Table 5Adverse Events^a

		<u>Placebo</u>	<u>Prazosin</u>
		<u>n(%) or M(SD)</u>	<u>n(%) or M(SD)</u>
Dizziness on standing	% endorsing; n(%)	5(35.7)	7(50.0)
	Days endorsed; M(SD)	1.9(3.6)	5.4(7.0)*
Headaches	% endorsing; n(%)	9(64.3)	7(50.0)
	Days endorsed; M(SD)	3.0(4.7)	4.5(7.9)
Lightheadedness	% endorsing; n(%)	6(42.9)	9(64.3)
	Days endorsed; M(SD)	3.8(7.8)	6.4(7.7)
Nausea	% endorsing; n(%)	9(64.3)	6(42.9)
	Days endorsed; M(SD)	2.9(4.5)	1.5(2.9)
Lack of energy	% endorsing; n(%)	8(57.1)	8(57.1)
	Days endorsed; M(SD)	7.8(8.9)	13.9(14.7)*
Drowsiness	% endorsing; n(%)	7(50.0)	9(64.3)
	Days endorsed; M(SD)	5.7(7.9)	19.0(18.8)**
Blood pressure drop sitting to standing	% observed; n(%)	0	1(7.1)

^aParticipants with at least 1 post-baseline visit (i.e., those receiving medication and providing information on adverse events/side effects at least 1 safety visit) were included here; n = 28.

* p < 0.10

** p < 0.05